
Inclacumab
CAS No. 1256258-86-2
Inclacumab( —— )
Catalog No. M37165 CAS No. 1256258-86-2
Inclacumab, a humanized monoclonal IgG4 antibody (Anti-Human Selectin P Recombinant Antibody), specifically binds to P-selectin with a dissociation constant (Kd) of 9.9 nM.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
2MG | 453 | Get Quote |
![]() ![]() |
5MG | 687 | Get Quote |
![]() ![]() |
10MG | 937 | Get Quote |
![]() ![]() |
25MG | 1371 | Get Quote |
![]() ![]() |
50MG | 1812 | Get Quote |
![]() ![]() |
500MG | Get Quote | Get Quote |
![]() ![]() |
1G | Get Quote | Get Quote |
![]() ![]() |
Biological Information
-
Product NameInclacumab
-
NoteResearch use only, not for human use.
-
Brief DescriptionInclacumab, a humanized monoclonal IgG4 antibody (Anti-Human Selectin P Recombinant Antibody), specifically binds to P-selectin with a dissociation constant (Kd) of 9.9 nM.
-
DescriptionInclacumab (Anti-Human selectin P Recombinant Antibody) is a humanized monoclonal IgG4 antibody selectively targets P-selectin with a Kd value of 9.9 nM. Inclacumab inhibits P-selectin glycoprotein ligand 1 (PSGL-1) mimetic peptide bind with P-selectin with an IC50 value of 1.9 μg/mL and strongly inhibits cell adhesion.
-
In VitroInclacumab (0.4-40 μg/mL; 5 min) significantly reduces flow adhesion of P-Selectin with Whole Blood (WB) and isolated White Blood Cell (I-WBC) and shows a morestronger effect on isolated white cells.Inclacumab shows great binding affinity to P-selectin with a Kd value of 9.9 nM.Inclacumab inhibits PSGL-1 mimetic peptide binding with P-selectin with an IC50 value of 1.9 μg/mL.Inclacumab blocks the adhesion of PSGL-1 expressing cells to an immobilized P-selectin with an IC50 value of 430 ng/mL.Inclacumab (0-100 μg/mL; 5min) dose-dependently inhibits thrombin receptor-activating peptide (TRAP)-induced platelet-leukocyte aggregates (PLA) levels with an IC50 value of 1.4 μg/mL.
-
In VivoInclacumab (4 mg/kg; s.c. once) reduces TRAP- and ADP-induced PLA levels in cynomolgus monkeys.Inclacumab (2-50 mg/kg; i.v.; once a week for 13 weeks) inhibits TRAP induced PLA levels in cynomolgus monkeys.Animal Model:Cynomolgus monkeys Dosage:4 mg/kg Administration:Subcutaneous injection; 4 mg/kg; once Result:Significantly reduced TRAP-induced PLA levels from 25% to 6% and supressed PLA formation ≥80% for at least 28 days post treatment. Remained plasma concentrations >20 μg/mL during post treatment for 28 days. Significantly inhibited the formation of ADP (10 μM)-induced PLAs.Animal Model:Cynomolgus monkeys Dosage:2, 10, and 50 mg/kg Administration:Intravenous injection; once daily; for 13 weeks Result:Inhibited TRAP-induced PLA and remained concentrations at all three dose levels are higher than 20 μg/mL. Persisted the full inhibition of PLA formation between dosing period.
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1256258-86-2
-
Formula Weight
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Tarasev M, et al. S107: P-SELECTIN INHIBITOR INCLACUMAB REDUCES CELL ADHESION IN AN IN-VITRO ASSAYS SHOWING POTENTIAL FOR PREVENTION OF VASO-OCCLUSION EVENTS IN SICKLE CELL DISEASE. Hemasphere. 2022 Jan 31;6(Suppl ):3-4.
molnova catalog



related products
-
Cimifugin 4-O-beta-D...
Cimifugin 4'-O-beta-D-glucopyranoside is a natural product.
-
Ajugasterone C
Ajugasterone C shows significant inhibitory effect at 100 mg/kg dose on rat paw oedema development due to carrageenan-induced inflammation in Sprague Dawley rats.
-
Spinosyn A
Spinosyn A is a polyketide-derived macrolide produced by Saccharopolyspora spinosa and is an active ingredient in several commercial insecticides.